
1. Technology overview
Xincere Med, legally Shanghai Xincere Medical Technology Co., Ltd., is a clinical trial technology company with its office at Room 818, Jinhui Building, No. 8 Wuzhong Road, Xuhui District, Shanghai. It focuses on decentralized clinical trial and eCOA solutions in CNS, dermatology, respiratory and oncology studies.
ePData is its integrated electronic clinical outcome assessment solution. Alongside it the company offers ePDiary, ePConsent, ePVisit, wearable connectivity (ePLink), scale management and rater training. Services include eCOA support, audit support, device provisioning and data archiving. The site reports 580+ research sites and 33,000+ subjects.
2. Highlighted features & specifications
- ePData: Integrated eCOA solution designed to reduce patient burden.
- ePScale: Scale management for compliant and fast use of instruments.
- Rater Training: Improves rater consistency and data quality.
- DCT modules: ePDiary, ePConsent, ePVisit, ePLink and sensor connectivity.
- Support services: eCOA support, audit support, technical support and site training.
- Operations: Device provisioning, data integrations and data archiving.
3. Potential application
A CRO in Southeast Asia could use ePData for patient diaries in a multi-country CNS study. A hospital research center could use eConsent and tele-visit modules to include remote participants in a trial.
4. Benefits
The vendor states international-standard quality verified by third parties and multilingual, multi-timezone support. A verified eCOA library and standardized processes shorten study setup. One platform covers eCOA, eConsent, tele-visits and wearables. The site reports 100+ DCT projects and 9+ regulatory inspections supported.
5. Market trends & opportunities
Sponsors across Asia are adopting eCOA and decentralized trial tools, and Xincere reports active collaboration discussions with Japanese partners. Vietnam and Southeast Asia studies run by multinational sponsors increasingly need multilingual, multi-timezone eCOA support.
6. Other information
Shanghai-based. In June 2026 it signed a dual long-term licensing agreement with EuroQol Research Foundation for COA work in China. Its team visited Japan in June 2025 to discuss collaboration with Buzzreach and 3H Medi Solution. Site footer shows copyright 2022; founding year not stated.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































